436 related articles for article (PubMed ID: 9531046)
1. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
3. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
5. Human gender differences in fibrinolytic responses to exercise training and their determinants.
Kulaputana O; Macko RF; Ghiu I; Phares DA; Goldberg AP; Hagberg JM
Exp Physiol; 2005 Nov; 90(6):881-7. PubMed ID: 16118237
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
7. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
10. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
Stegnar M; Mavri A
Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
[TBL] [Abstract][Full Text] [Related]
14. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
15. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
16. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
17. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects].
Xiong X; Wang Z; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745
[TBL] [Abstract][Full Text] [Related]
19. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]